Nocion Therapeutics is a biopharmaceutical company developing novel small molecule CSCBs, nocions, that selectively affect actively firing nociceptors for the treatment of serious conditions involving cough, itch, and pain. The company's mission is to safely alleviate suffering for millions of patients with conditions arising from activated sensory neurons. Working with Harvard's Office of Technology Development, Nocion was founded on an exclusive license to foundational intellectual property from Harvard University and Boston Children's Hospital.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 03/04/24 | $62,000,000 | Series B |
Arkin Bio Ventures Canaan Partners F-Prime Capital Partners Mass General Brigham Ventures Mission BioCapital Monograph Capital Osage University Partners | undisclosed |
